Drug Trial Radar · NCT05852938
A Study of Zigakibart in Adults With IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
383
Actual
Start
Jul 6, 2023
Primary completion
Aug 10, 2027
Study completion Jan 25, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Conditions
- IgA Nephropathy
- Immunoglobulin A Nephropathy
Interventions
BION-1301Drug
BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
PlaceboDrug
Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in eGFRTime frame: Baseline and 104 weeks or approximately 2 years
Locations
200 sites in 23 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham: The Kirklin Clinic
Birmingham, Alabama
Nephrology Consultants, LLC
Huntsville, Alabama
University of California, San Francisco
San Francisco, California
Valiance Clinical Research
South Gate, California
University of Colorado Hospital
Aurora, Colorado
Denver Nephrology Research Division
Denver, Colorado
Vida Medical Centers - Pembroke Pines
Pembroke Pines, Florida
NorthShore University HealthSystem
Evanston, Illinois
Nephrology Associales of Northern Illinois and Indiana
Hinsdale, Illinois
Nephrology Associates of Northern Illinois and Indiana - 7836 W Jefferson Blvd
Fort Wayne, Indiana
University Of Iowa Hospitals And Clinics
Iowa City, Iowa
Intermed Consultants
Edina, Minnesota
Capital District Renal Physicians
Clifton Park, New York
Nephrology Associates PC - Flushing
Flushing, New York
Icahn School of Medicine at Mount Sinai
New York, New York
University of Cincinnati College of Medicine - 231 Albert Sabin Way
Cincinnati, Ohio
Cleveland Clinic-9500 Euclid Ave
Cleveland, Ohio
OHSU - Oregon Clinical and Translational Research Institute
Portland, Oregon
Northeast Clinical Research Center, LLC
Bethlehem, Pennsylvania
Columbia Nephrology Associates , P.A. - Columbia
Columbia, South Carolina
Knoxville Kidney Center, PLLC - Frenova F1
Knoxville, Tennessee
Dallas Renal Group - 1411 N Beckley Ave
Dallas, Texas
Dallas Renal Group - Waxachie - 2460 N. I-35
Dallas, Texas
DaVita Clinical Research
El Paso, Texas
University of Texas MD Anderson Cancer Center-1155 Pressler
Houston, Texas
East Texas Nephrology Associates
Lufkin, Texas
Nephrology Associates of Northern Virginia-8501 Arlington Blvd
Fairfax, Virginia
Swedish Center for Comprehensive Care
Seattle, Washington
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Catamarca, Catamarca Province, Argentina
Novartis Investigative Site
Barracas, Ciudad Autónoma de BuenosAires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Santa Fe, Santa Fe Province, Argentina
Novartis Investigative Site
Gosford, New South Wales, Australia
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Liverpool, New South Wales, Australia
Novartis Investigative Site
Penrith, New South Wales, Australia
Novartis Investigative Site
St Leonards, New South Wales, Australia
Novartis Investigative Site
Cairns North, Queensland, Australia
Showing 40 of 200 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.